CYTK - Cytokinetics, Incorporated

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.21
-0.13 (-1.77%)
At close: 4:00PM EST

7.49 +0.28 (3.88%)
After hours: 5:37PM EST

Stock chart is not supported by your current browser
Previous Close7.34
Open7.35
Bid7.50 x 2200
Ask7.94 x 1300
Day's Range7.17 - 7.45
52 Week Range5.90 - 10.00
Volume1,139,902
Avg. Volume312,541
Market Cap394.466M
Beta (3Y Monthly)2.08
PE Ratio (TTM)N/A
EPS (TTM)-2.22
Earnings DateFeb 21, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.33
Trade prices are not sourced from all markets
  • Cytokinetics (CYTK) Reports Q4 Loss, Tops Revenue Estimates
    Zacks2 hours ago

    Cytokinetics (CYTK) Reports Q4 Loss, Tops Revenue Estimates

    Cytokinetics (CYTK) delivered earnings and revenue surprises of 12.73% and 171.40%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press3 hours ago

    Cytokinetics: 4Q Earnings Snapshot

    The South San Francisco, California-based company said it had a loss of 48 cents per share. The biopharmaceutical company posted revenue of $9.4 million in the period. For the year, the company reported ...

  • GlobeNewswire3 hours ago

    Cytokinetics Reports Fourth Quarter 2018 Financial Results

    Company Provides 2019 Financial Guidance and Expected Milestones Reduced Operating Expenses vs. 2018; Over Two Years of Cash Based on Current Burn Rate Interim Analysis for.

  • GlobeNewswire10 hours ago

    Amgen, Cytokinetics and Servier Announce Start of METEORIC-HF, the Second Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure

    THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. and SURESNES, France, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Amgen (AMGN), Cytokinetics, Incorporated (CYTK) and Servier today announced that METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil Related to Increased Contractility in Heart Failure), the second Phase 3 clinical trial of omecamtiv mecarbil, a novel cardiac myosin activator, is open to enrollment. Omecamtiv mecarbil is being developed for the potential treatment of heart failure with reduced ejection fraction (HFrEF). METEORIC-HF is designed to evaluate the effect of treatment with omecamtiv mecarbil compared to placebo on exercise capacity as determined by cardiopulmonary exercise testing (CPET) in patients with HFrEF.

  • PR Newswire10 hours ago

    Amgen, Cytokinetics And Servier Announce Start Of METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure

    THOUSAND OAKS, Calif., SOUTH SAN FRANCISCO, Calif., and SURESNES, France, Feb. 21, 2019 /PRNewswire/ -- Amgen (AMGN), Cytokinetics, Incorporated (CYTK) and Servier today announced that METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil Related to Increased Contractility in Heart Failure), the second Phase 3 clinical trial of omecamtiv mecarbil, a novel cardiac myosin activator, is open to enrollment. Omecamtiv mecarbil is being developed for the potential treatment of heart failure with reduced ejection fraction (HFrEF). METEORIC-HF is designed to evaluate the effect of treatment with omecamtiv mecarbil compared to placebo on exercise capacity as determined by cardiopulmonary exercise testing (CPET) in patients with HFrEF.

  • GlobeNewswireyesterday

    Cytokinetics Announces Initiation of Phase 1 Clinical Study of AMG 594, a Cardiac Troponin Activator

    Cytokinetics, Incorporated (CYTK) today announced that the first subject has been dosed in a Phase 1, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 594 in healthy subjects. AMG 594 is a cardiac troponin activator, discovered under a joint research program conducted between Amgen and Cytokinetics. The study is being conducted by Amgen in collaboration with Cytokinetics.

  • The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna
    Zacks7 days ago

    The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna

    The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna

  • Will Cytokinetics (CYTK) Report Negative Earnings Next Week? What You Should Know
    Zacks7 days ago

    Will Cytokinetics (CYTK) Report Negative Earnings Next Week? What You Should Know

    Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • 5 Tiny Biotech Stocks With Superb Growth Potential
    Zacks8 days ago

    5 Tiny Biotech Stocks With Superb Growth Potential

    A spurt in deal-making has boosted the sector this year which retains the ability to provide outsized gains.

  • GlobeNewswire14 days ago

    Cytokinetics to Announce Fourth Quarter Results on February 21, 2019

    Cytokinetics, Incorporated (CYTK) today announced that it is scheduled to report fourth quarter results on February 21, 2019 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future. The conference call will be simultaneously webcast and can be accessed from the homepage and in the Investors & Media section of Cytokinetics’ website at www.cytokinetics.com.

  • GlobeNewswirelast month

    Cytokinetics Announces Receipt of FDA Feedback Regarding Reldesemtiv in Patients With SMA

    Cytokinetics, Incorporated (CYTK) today announced that it has received feedback from the U.S. Food and Drug Administration (FDA) that the Six Minute Walk Test (6MWT) is an acceptable primary efficacy endpoint for a potential registration program for reldesemtiv in patients with spinal muscular atrophy (SMA) who have maintained ambulatory function. In collaboration with Astellas, Cytokinetics is developing reldesemtiv as a potential treatment for people with SMA and certain other debilitating diseases and conditions associated with skeletal muscle weakness and/or fatigue. The companies are discussing potential next steps regarding the ongoing development program for reldesemtiv in this patient population.

  • Could Cytokinetics, Incorporated’s (NASDAQ:CYTK) Investor Composition Influence The Stock Price?
    Simply Wall St.2 months ago

    Could Cytokinetics, Incorporated’s (NASDAQ:CYTK) Investor Composition Influence The Stock Price?

    The big shareholder groups in Cytokinetics, Incorporated (NASDAQ:CYTK) have power over the company. Institutions often own shares in more established companies, while it's not unusual to see insiders own a Read More...

  • Hedge Funds Are Dumping Cytokinetics, Inc. (CYTK)
    Insider Monkey2 months ago

    Hedge Funds Are Dumping Cytokinetics, Inc. (CYTK)

    It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity. As a result, most investors pick their illusory “winners” by making a superficial analysis and research that leads to poor performance on aggregate. Since stock returns aren’t usually symmetrically distributed and index […]

  • GlobeNewswire2 months ago

    Cytokinetics Announces New Data Presented at the International Symposium on ALS/MND

    SOUTH SAN FRANCISCO, Calif., Dec. 10, 2018 -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new data were presented at the 29th International Symposium on.

  • GlobeNewswire3 months ago

    Cytokinetics Announces Initiation of Phase 1 Clinical Trial of CK-3773274, a Cardiac Myosin Inhibitor

    Cytokinetics, Incorporated (CYTK) today announced the first subject has been dosed in a Phase 1 double-blind, randomized, placebo-controlled, multi-part, single and multiple ascending dose clinical trial of CK-3773274 (CK-274) in healthy adult subjects. CK-274 is a novel cardiac myosin inhibitor, discovered by company scientists, in development for the potential treatment of hypertrophic cardiomyopathy (HCM). “The start of clinical trials for CK-274 marks an important milestone in our continuing innovation of potential sarcomere-directed medicines,” said Fady I. Malik, M.D., Ph.D., Cytokinetics’ Executive Vice President of Research & Development.

  • Benzinga3 months ago

    Jim Cramer Gives His Opinion On Netflix, Kraft Heinz And More

    On CNBC's "Mad Money Lightning Round,"  Jim Cramer said he isn't a fan of Netflix, Inc. (NASDAQ: NFLX ) because the content isn't as compelling as it once was. He sees it as a good story, but ...

  • GlobeNewswire3 months ago

    Analysis: Positioning to Benefit within Abeona Therapeutics, Great Lakes Dredge & Dock, Imprimis Pharmaceuticals, Alliant Energy, Cytokinetics, and Aurinia Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire3 months ago

    Cytokinetics Completes Enrollment in FORTITUDE-ALS, Phase 2 Clinical Trial of Reldesemtiv in Patients With ALS

    Cytokinetics, Incorporated (CYTK) today announced the completion of patient enrollment in FORTITUDE-ALS (Functional Outcomes in a Randomized Trial of Investigational Treatment with CK-2127107 to Understand Decline in Endpoints – in ALS), the Phase 2 clinical trial designed to assess the change from baseline in the percent predicted slow vital capacity (SVC) and other measures of skeletal muscle function after 12 weeks of treatment with reldesemtiv (formerly CK-2127107). In collaboration with Astellas Pharma Inc. (TSE:4503) (“Astellas”), Cytokinetics is developing reldesemtiv, a next-generation fast skeletal muscle troponin activator (FSTA), as a potential treatment for people living with debilitating diseases and conditions associated with skeletal muscle weakness and/or fatigue.

  • GlobeNewswire3 months ago

    Cytokinetics Announces Five Presentations at the International Symposium on ALS/MND

    SOUTH SAN FRANCISCO, Calif., Nov. 26, 2018 -- Cytokinetics, Inc. (Nasdaq: CYTK) today announced five poster presentations at the 29th International Symposium on ALS/MND in.

  • Cytokinetics Sees Hammer Chart Pattern: Time to Buy?
    Zacks3 months ago

    Cytokinetics Sees Hammer Chart Pattern: Time to Buy?

    Cytokinetics has been struggling lately, but the selling pressure may be coming to an end soon.

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of CYTK earnings conference call or presentation 1-Nov-18 8:30pm GMT

    Q3 2018 Cytokinetics Inc Earnings Call

  • Cytokinetics (CYTK) Reports Q3 Loss, Tops Revenue Estimates
    Zacks4 months ago

    Cytokinetics (CYTK) Reports Q3 Loss, Tops Revenue Estimates

    Cytokinetics (CYTK) delivered earnings and revenue surprises of 24.53% and 377.18%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press4 months ago

    Cytokinetics: 3Q Earnings Snapshot

    On a per-share basis, the South San Francisco, California-based company said it had a loss of 40 cents. The biopharmaceutical company posted revenue of $10.6 million in the period. Cytokinetics shares ...